FOUNDATIONAL WORK FOR A NATIONAL RESEARCH PROGRAM IN ORGAN DONOR CARE

This thesis is divided in three chapters: (i) introduction to organ donation, (ii) rationale, implementation and design of a pilot observational study currently underway and (iii) justification for use of a waived consent model for observational research studies on organ donor care. Organ donation is a complex event that remains a mystery to most health care providers. The first chapter reports knowledge gaps in clinical management of deceased organ donors across Canada and summarizes ongoing trials in organ donor care. The persistent deficit in transplantable organs along with the limited scientific evidence to guide the clinical management of the organ donor justify the need for a national research program in organ donor care. There are logistical and methodological challenges unique to the design and conduct of research on deceased donors. To identify potential stakeholders involved in the process of organ donation and to provide an accurate description of usual management of deceased donor and assess its variability, we developed and initiated a prospective observational study called DONATE. The second chapter of this thesis described the pilot phase of this study. It contains the following sections: i) objectives of the study ii) the screening process, iii) data collection, iv) clinical outcomes, v) methods of measurement, vi) analysis plan and vii) strategies used to minimize the biases inherent to observational studies. The normative goal of obtaining informed consent from participants may not be appropriate for an observational study in organ donor care. The third chapter summarizes the justification for use of a waived consent model for observational studies of organ donation medicine. In this chapter, I discuss regulatory, ethical and logistical issues relevant to use of a waived consent model in organ donation research.ThesisMaster of Science (MSc)Organ donation saves lives and it is the most effective therapy available to treat end stage organ failure of a number of organs. Unfortunately, there is a growing gap between the number of donors and the number of patients waiting for transplantation. This thesis summarizes the foundational work of a national research program in deceased donor management. It describes the study design of a 4 centre prospective observational study in deceased donor management with outcome assessment on corresponding organ-recipients. This thesis also contains a justification for waiving the procurement of consent to research on organ donor management. Finally, it will inform investigators of future national multicentre observational studies on design and implementation issues related to donor management, in order to improve care provided to donors and outcomes of recipients while reducing the gap between transplant needs and organ supply

Program of Uncontrolled Donation After Circulatory Death as Potential Solution to the Shortage of Organs: A Canadian Single-Center Retrospective Cohort Study

Purpose: Worldwide, the number of patients waiting for organ transplantation exceeds the number of organs available. Program for uncontrolled donation after circulatory death (uDCD) implemented in Europe has resulted in a 10?15% expansion of the donor pool. We aimed to describe the number of patients eligible for an uDCD program in a regional tertiary care center. Methods: We conducted a retrospective cohort study in a Canadian tertiary academic center located in a rural area including all adults who received cardiopulmonary resuscitation in 2016 and died in the emergency department (ED) or during their hospitalization. The primary outcome was the number of patients eligible for uDCD defined as aged between 18 and 60 years old whose collapse was witnessed and where the time between cardiac arrest to cardiopulmonary resuscitation and ED arrival was, respectively, less than 30 and 120 minutes. As a secondary outcome, we determined the number of patients eligible for controlled donation after circulatory death. Results: Of the 130 patients included, 84 did not return to spontaneous circulation. We identified 15 potential uDCD candidates, with a mean age of 46.6 (95% Confidence Interval [CI] 41.3 to 52) years. Twelve had an out-of-hospital cardiac arrest with a mean time between collapse and arrival to the ED of 43.2 (29.8 to 56.6) minutes. Among the 46 patients who died after a return of spontaneous circulation, 10 (21.7%) were eligible for organ donation after circulatory death. Conclusion: Implementing an uDCD program in a tertiary hospital covering a rural area could increase the number of donors

MIMIC-Extract: A Data Extraction, Preprocessing, and Representation Pipeline for MIMIC-III

Robust machine learning relies on access to data that can be used with standardized frameworks in important tasks and the ability to develop models whose performance can be reasonably reproduced. In machine learning for healthcare, the community faces reproducibility challenges due to a lack of publicly accessible data and a lack of standardized data processing frameworks. We present MIMIC-Extract, an open-source pipeline for transforming raw electronic health record (EHR) data for critical care patients contained in the publicly-available MIMIC-III database into dataframes that are directly usable in common machine learning pipelines. MIMIC-Extract addresses three primary challenges in making complex health records data accessible to the broader machine learning community. First, it provides standardized data processing functions, including unit conversion, outlier detection, and aggregating semantically equivalent features, thus accounting for duplication and reducing missingness. Second, it preserves the time series nature of clinical data and can be easily integrated into clinically actionable prediction tasks in machine learning for health. Finally, it is highly extensible so that other researchers with related questions can easily use the same pipeline. We demonstrate the utility of this pipeline by showcasing several benchmark tasks and baseline results

Atraumatic (pencil-point) versus conventional needles for lumbar puncture:a clinical practice guideline

Is the needle tip configuration important when performing a lumbar puncture for any indication? A systematic review published in the Lancet in December 2017 suggests that it is. The review found that using atraumatic (pencil-point) lumbar puncture needles instead of conventional lumbar puncture needles reduced the risk of post-dural-puncture headache and of return to hospital for additional pain control.1 This guideline recommendation aims to promptly and transparently translate this evidence to a clinical recommendation, following standards for GRADE methodology and trustworthy guidelines.2 The BMJ Rapid Recommendations panel makes a strong recommendation for the use of atraumatic needles for lumbar puncture in all patients regardless of age (adults and children) or indication instead of conventional needles.3 4 Box 1 shows the article and evidence linked to this Rapid Recommendation. The main infographic provides an overview of the absolute benefits and harms (although none were present here) of atraumatic needles. Table 1 below shows any evidence that has emerged since the publication of this guideline.publishedVersio

Small-Volume Tubes to Reduce Anemia and Transfusion (STRATUS): A Pragmatic Stepped Wedge Cluster Randomized Trial

Background: Intensive care unit (ICU) patients undergo frequent blood sampling for laboratory testing resulting in blood loss that contributes to anemia and red blood cell (RBC) transfusion. Only 10% of the blood collected is used for testing suggesting that lower sample volumes may reduce the incidence/severity of anemia and use of RBC transfusion without compromising care. Small-volume (soft-draw) Vacutainer® tubes for blood collection (2-3 mL) have the same cost, physical dimensions, and blood draw technique as standard-volume tubes (4-10 mL) and are compatible with laboratory analyzers. We previously conducted a mixed-methods pilot study (n=369) in which small-volume tubes were implemented in the ICU resulting in a 45% reduction in blood loss with acceptability to end-users and no increased frequency of inadequate samples. We are currently conducting the STRATUS trial, a multi-center stepped wedge cluster randomized trial to determine whether a policy of using small-volume blood collection tubes reduces RBC transfusion compared to standard-volume tubes in adult ICU patients. Using this design an intervention can be incorporated into everyday practice at a site of care (such as an ICU) where individual randomization is not feasible. It is ideal for studying the effectiveness and implementation of interventions that have a high likelihood of benefit and low risk of harm. Study Design and Methods: STRATUS is a pragmatic stepped wedge cluster randomized trial being conducted at 25 ICUs (clusters) in Canada over 18 months. At 6-week intervals (steps), 2 ICUs are randomly selected to switch from standard-volume tubes (control) to small-volume tubes (intervention) for blood sampling. All patients admitted to the ICU during the study period are enrolled with waived consent and undergo blood sampling using the allocated tubes. To be eligible for STRATUS, ICUs met the following criteria: (i) adult care only (≥18 years), (ii) unit size ≥14 beds, (iii) capacity for mechanical ventilation; (iv) use of standard-volume Vacutainer® blood collection tubes at baseline; and (v) availability of electronic administrative and laboratory information. The primary outcome is the number of RBC units transfused per patient during their ICU stay in patients admitted to ICU for ≥48 hours. Secondary outcomes include (i) number of RBC units transfused per patient for the entire cohort, (ii) percentage change in estimated blood loss; (iii) change in hemoglobin concentration from ICU admission to discharge adjusted for RBC transfusion; (iv) number of samples with inadequate volume for testing; (v) ICU and hospital mortality; and (vi) ICU and hospital length of stay. The study is approved by local and provincial research ethics boards. Data are collected from electronic administrative and health record sources. Assuming a power of 90% with a type I error of 5% (2-sided) and intra-cluster correlation coefficient (ICC) of 0.01, 25 sites with 729 patients per site (total 18,240 ICU patients) are required to detect a minimum difference of 5 units per 100 patients (or 2.5% reduction). As the interventions are applied in hospital, we expect minimal loss to follow-up. From trial initiation January 2, 2019 to August 1, 2019, 6 sites have been switched to small-volume blood collection tubes on schedule. Up to May 2, 2019 enrolment was 4,186 patients. Significance: STRATUS will determine whether the use of small-volume blood collection tubes reduces RBC transfusion in ICU patients using an innovative cluster trial design that incorporates the intervention into routine ICU practice. With electronic administrative and health record data collection and a clinically relevant primary outcome, this pragmatic trial has the potential to change blood collection practices widely. Disclosures Siegal: Portola: Honoraria; BMS-Pfizer: Honoraria; Novartis: Honoraria; Bayer: Honoraria; Leo Pharma: Honoraria; Aspen Pharma: Honoraria. Arnold:Novartis: Honoraria, Research Funding; Rigel: Consultancy, Research Funding; Bristol-Myers Squibb: Research Funding; Principia: Consultancy. Connolly:Bayer Healthcare: Consultancy, Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding; Portola Pharmaceuticals: Consultancy, Research Funding; Daiichi Sankyo: Consultancy, Research Funding. Crowther:Octapharma: Membership on an entity's Board of Directors or advisory committees; Shionogi: Membership on an entity's Board of Directors or advisory committees; Alexion: Speakers Bureau; Asahi Kasei: Membership on an entity's Board of Directors or advisory committees; CSL Behring: Other: preparing educational material and/or providing educational presentations; Pfizer: Other: preparing educational material and/or providing educational presentations; Servier Canada: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; BMS Canada: Membership on an entity's Board of Directors or advisory committees, Research Funding; Bayer: Other: Data and Safety Monitoring Board, Research Funding, Speakers Bureau; Diagnostica Stago: Other: preparing educational material and/or providing educational presentations, Research Funding; Alnylam: Equity Ownership. </jats:sec